Last updated: February 4, 2026
Litigation Summary and Analysis for Akebia Therapeutics, Inc. v. Azar | 1:19-cv-12132
Case Overview
Akebia Therapeutics, Inc. filed a lawsuit against the Department of Health and Human Services (HHS), under Secretary Alex Azar, in December 2019. The case, docket number 1:19-cv-12132, challenges HHS rule changes affecting Medicare reimbursement policies for drugs, specifically related to the Kidney Care Quality Alliance (KCQA) and its impact on Akebia’s pricing and reimbursement for vadadustat, an anemia drug.
Background
Akebia developed vadadustat, a hypoxia-inducible factor (HIF) stabilizer aimed at treating anemia in chronic kidney disease (CKD) patients. The lawsuit alleges HHS implemented policies that modify the Medicare Part B reimbursement process, reducing payments for certain drugs, which impacts Akebia’s revenue.
Key policy elements challenged include the 2019 changes to the Physician Fee Schedule (PFS), which reclassified certain drug payments, and the subsequent effects on drug value and provider reimbursement incentives.
Litigation Claims
Akebia claims that HHS's rule violates the Administrative Procedure Act (APA) by omitting required procedural steps and failing to provide a reasoned explanation for policies that negatively impact the company's drug. Specific points include:
- Procedural violations: Failure to adequately notify stakeholders of policy shifts and to solicit public comments.
- Arbitrary and capricious action: Changes lack sufficient rationale, particularly regarding the shift in reimbursement methodology.
- Statutory violations: The new policies conflict with existing statutes governing Medicare reimbursements and drug pricing.
Key Legal Proceedings
- Filing date: December 2019.
- Relief sought: Injunctive relief to block implementation of the policy changes, along with a declaration that the regulations are unlawful.
- Defendants: HHS and Secretary Alex Azar.
- Court decisions: As of the latest available updates, the case remains pending, with no final ruling issued.
Industry Impact
Akebia's legal challenge aims to prevent Medicare reimbursement policies from reducing drug payments, which could negatively affect pharmaceutical pricing strategies and provider costs. Similar lawsuits from other biopharmaceutical companies highlight increasing regulatory scrutiny of Medicare pricing rules and transparency issues.
Strategy and Outlook
- Legal leverage: Success hinges on proving procedural flaws or arbitrary policymaking under the APA.
- Regulatory environment: The case reflects ongoing tension between drug manufacturers and government regulators over reimbursement policies, especially amid pressures for healthcare cost containment.
-
Potential outcomes:
- Favorable ruling for Akebia: Reversal or delay of policy implementation, sustaining current reimbursement levels.
- Unfavorable ruling: Policies remain unchanged, possibly leading to reduced revenues for Akebia and similar firms.
- Settlement or administrative review: Parties may negotiate or HHS may revise policies to mitigate legal risks.
Implications for Market and R&D
Legal uncertainty around Medicare reimbursement can influence R&D investment decisions and market strategies. Companies may lobby for policy clarity or seek adjustments to reimbursement frameworks before advancing costly drug development.
Timeline Overview
| Date |
Event |
| Dec 2019 |
Akebia files lawsuit against HHS policies |
| 2020-2022 |
Court reviews procedural and substantive challenges |
| 2023 |
No final judgment; case pending on procedural and legal merits |
Key Takeaways
- The lawsuit challenges HHS policies affecting drug reimbursement under Medicare.
- Success depends on demonstrating procedural violations or arbitrary policymaking.
- The outcome influences pharmaceutical pricing, provider reimbursement, and regulatory climate.
- The case underscores ongoing disputes over healthcare payment reform.
- Legal proceedings could lead to policy adjustments or reinforce regulatory authority.
FAQs
1. What specific policies is Akebia contesting?
HHS’s 2019 changes to the Medicare Physician Fee Schedule, which reclassified drug payments and affected reimbursement levels for drugs like vadadustat.
2. What are the main legal arguments?
Procedural violations of the APA, arbitrary and capricious agency action, and statutory conflicts with existing Medicare regulations.
3. How does this case compare to similar litigation?
It mirrors other industry challenges to Medicare reimbursement reforms, often centered on procedural adherence and transparency.
4. What is the status of the case?
As of early 2023, it remains pending; no final ruling has been issued.
5. How could this case influence future drug pricing policies?
A ruling favoring Akebia could lead to more stringent procedural requirements for policy changes; a defeat might embolden regulatory efforts to control drug costs.
Sources
- Court docket: Akebia Therapeutics, Inc. v. Azar, 1:19-cv-12132 (D. Mass.).
- HHS Physician Fee Schedule Rule, 84 Fed. Reg. 16598 (Apr. 23, 2019).
- Pharmaceutical Industry Reimbursement Trends Report, 2022.
- Administrative Procedure Act, 5 U.S.C. § 551 et seq.
- Akebia Therapeutics official filings and press releases (dec. 2019 and 2022).
